Last year, the therapy received a positive opinion from the EMA’s CHMP.
News
Sanofi, Babylon link-up to tackle digestive health
Only an estimated 30% of people in the UK who suffer from IBS have actually been diagnosed and, of those, 61% often mistreat their symptoms with analgesics or antacids.
Givlaari approved in EU following recent CHMP nudge
The drug is a first-of-its kind injectable RNAi therapeutic.
Orphan drugs face “uphill battle” in 2020
EMA-assigned Orphan Drug Designations declined 49% between 2014 and 2019.
COVID-19: Takeda, Arcturus, Veeva all chip in
The UK has reported its biggest overnight jump in cases, bringing the total to 87 infected patients.
2020 International Clinical Researcher of the Year postponed until September
The 2020 International Clinical Researcher of the Year competition has been postponed until the end of September/beginning of October.
Four pharma companies found guilty of anti-competitive behaviour
Ultimately, the CMA is fining King and Accord-UK £75,573 and £1,882,238 respectively, with Accord-UK and Auden agreeing to make a £1 million payment to the NHS.
App to determine risk of preterm birth developed
When babies are born early, before 37 weeks of pregnancy, they are more likely to die, or have physical, developmental and emotional problems.
First patient dosed in potential lymphoedema treatment trial
The drug being evaluated is an oral, small molecule drug candidate known as deupirfenidone.
FDA approves Sarclisa for relapsed refractory multiple myeloma
The approval of the monoclonal antibody “provides a new treatment option for patients whose disease has returned or become resistant to their prior treatments.”
Xpovio hits endpoints in Phase III multiple myeloma trial
The drug achieved a median progression-free survival of 13.93 months, compared to 9.46 months on Velcade (bortezomib).
Keytruda improves PFS in classical Hodgkin lymphoma
The drug went head-to-head with brentuximab vedotin (BV) – also sold as Adcetris by Seattle Genetics.
Gilead strikes $4.9bn deal to buy Forty Seven
The acquisition is set to strengthen Gilead’s immuno-oncology research and development portfolio with drugs such as Forty Seven’s magrolimab.
GW Pharma regains Sativex rights in UK
The company is taking the reins back from Bayer.
EMA PRIME status granted to Janssen’s inherited retinal disease gene therapy
The designation makes the drug the only XLRP treatment in development to be awarded PRIME designation.
